Same active ingredient, different products
Both Ozempic and Wegovy contain semaglutide and are manufactured by Novo Nordisk. The difference is in:
- FDA-approved indication. Ozempic: type 2 diabetes (2017), cardiovascular risk reduction in T2D with established CV disease (2020). Wegovy: chronic weight management (2021), adolescent weight management (2022), cardiovascular risk reduction in adults with established CV disease and overweight/obesity (2024).
- Maximum approved dose. Ozempic goes up to 2.0 mg weekly. Wegovy goes up to 2.4 mg weekly.
- Pen device and titration schedule. Different injector pens, different starting doses, different escalation timelines.
- Insurance coverage. T2D indications are commonly covered. Weight management is variably covered.
Ozempic vs Wegovy at a glance
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA indication | Type 2 diabetes; CV risk in T2D | Weight management; CV risk in CVD with overweight/obesity |
| Dose range | 0.25, 0.5, 1.0, 2.0 mg weekly | Titrated to 2.4 mg weekly |
| Mean weight loss | Variable (off-label use) | ~14.9% at 68 weeks (STEP-1) |
| List price (approx.) | $1,000/month | $1,350/month |
| Insurance coverage | Commonly covered for T2D | Variable for weight management |
Can Ozempic produce weight loss?
Yes — weight loss is a common effect of any GLP-1 receptor agonist. In SUSTAIN trials of Ozempic for diabetes, mean weight loss at 1 mg or 2 mg doses was meaningful (4-7% at trial endpoints). However, prescribing Ozempic specifically for weight loss in a patient without type 2 diabetes is off-label. Insurance is much less likely to cover off-label use, and clinicians may prefer to use the on-label Wegovy formulation at 2.4 mg for patients whose primary goal is weight management.
Get clarity on which product fits your situation
A licensed clinician can review your indication, insurance, and goals to recommend Ozempic, Wegovy, or another GLP-1 option.
See If You Qualify →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure
Zepbound (tirzepatide) versus Wegovy
If the goal is weight management and the choice is between Wegovy and Zepbound, both are FDA-approved for chronic weight management. They are different molecules with different mechanisms:
- Wegovy: semaglutide; single GLP-1 receptor agonist; 2.4 mg weekly.
- Zepbound: tirzepatide; dual GLP-1/GIP receptor agonist; up to 15 mg weekly.
| Factor | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 / GIP receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Max dose | 2.4 mg weekly | 15 mg weekly |
| Mean weight loss (Phase 3) | ~14.9% (STEP-1, 68 wk) | ~20.9% (SURMOUNT-1, 72 wk) |
| Head-to-head data | SURMOUNT-5 (2025): semaglutide produced less weight loss | SURMOUNT-5: tirzepatide produced more weight loss |
| Approved indications | Weight; CV risk reduction; OSA; adolescents | Weight; OSA in obesity |
| List price (approx.) | $1,350/month | $1,060/month |
| Self-pay channel | NovoCare cash-pay | LillyDirect (vials ~$349-$499) |
How to choose between Ozempic, Wegovy, and Zepbound
- You have type 2 diabetes. Ozempic or Mounjaro are typical first choices when GLP-1 is appropriate. Both have cardiovascular outcome data in T2D. Either can be considered.
- Your primary goal is weight management without diabetes. Wegovy or Zepbound are the on-label weight management options. Zepbound has shown larger mean weight loss in trials and head-to-head.
- You have both T2D and obesity. Ozempic / Wegovy or Mounjaro / Zepbound; insurance and clinical fit matter.
- You have established cardiovascular disease. Wegovy (CV risk reduction in CVD with overweight/obesity) and Ozempic (CV risk reduction in T2D with CVD) have specific FDA indications.
- Insurance reality. Coverage rules often drive the choice in practice — the product your plan covers at the lowest copay is often the most accessible option.
- Side effect history. If you have tried semaglutide and had intolerable side effects, switching to tirzepatide (with appropriate re-titration) may be considered.
Switching between GLP-1 products
Switching between Ozempic, Wegovy, Mounjaro, Zepbound, or other GLP-1 agents should be done under clinician supervision. Key considerations:
- Different products are not interchangeable at "equivalent" doses; titration is usually restarted at the standard starting dose.
- Different products have different half-lives; timing matters.
- Insurance formularies often shift between products; switching can be driven by coverage as well as clinical preference.
Bottom line
Ozempic vs Wegovy is not really a clinical comparison — they are the same drug optimized for different patient populations. The more substantive comparison for weight management is Wegovy (semaglutide 2.4 mg) versus Zepbound (tirzepatide up to 15 mg), where Zepbound has produced larger mean weight loss in clinical trials and in head-to-head studies. The right product for any individual depends on indication, insurance coverage, side effect history, and clinician judgment.
Compare options with a licensed provider
A telehealth clinician can review your situation and recommend the GLP-1 medication that fits your indication, goals, and budget.
Check Your Eligibility →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure